Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Accounts Payables: 2019-2025

Historic Accounts Payables for Beam Therapeutics (BEAM) over the last 6 years, with Sep 2025 value amounting to $9.5 million.

  • Beam Therapeutics' Accounts Payables rose 150.39% to $9.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $9.5 million, marking a year-over-year increase of 150.39%. This contributed to the annual value of $3.9 million for FY2024, which is 139.39% up from last year.
  • Latest data reveals that Beam Therapeutics reported Accounts Payables of $9.5 million as of Q3 2025, which was down 9.58% from $10.6 million recorded in Q2 2025.
  • Beam Therapeutics' 5-year Accounts Payables high stood at $14.1 million for Q1 2023, and its period low was $1.6 million during Q4 2023.
  • Over the past 3 years, Beam Therapeutics' median Accounts Payables value was $4.4 million (recorded in 2024), while the average stood at $6.2 million.
  • Its Accounts Payables has fluctuated over the past 5 years, first tumbled by 82.09% in 2023, then spiked by 175.95% in 2025.
  • Beam Therapeutics' Accounts Payables (Quarterly) stood at $7.5 million in 2021, then grew by 20.81% to $9.0 million in 2022, then plummeted by 82.09% to $1.6 million in 2023, then skyrocketed by 139.39% to $3.9 million in 2024, then skyrocketed by 150.39% to $9.5 million in 2025.
  • Its Accounts Payables was $9.5 million in Q3 2025, compared to $10.6 million in Q2 2025 and $7.7 million in Q1 2025.